Multiple Myeloma Clinical Trials

168 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

   The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilt…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   University of California San Francisco, San Francisco, California

   Locations

   20 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07149857 on ClinicalTrials.gov

2. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Phoenix, Phoenix, Arizona

   Locations

   150 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

3. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

   This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Duarte, Duarte, California

   Locations

   6 in total

   Run by

   Fortvita Biologics (USA)Inc.

   See if you can join NCT07336472 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   173 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

5. Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

   Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple my…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT05789303 on ClinicalTrials.gov

6. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

   This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

   Stage

   Not phased

   Ages

   18 and older

   Site

   OHSU Knight Cancer Institute, Portland, Oregon

   Run by

   OHSU Knight Cancer Institute

   See if you can join NCT06784167 on ClinicalTrials.gov

7. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

8. Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

   This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey

   Run by

   Hackensack Meridian Health

   See if you can join NCT03909412 on ClinicalTrials.gov

9. A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

   This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma patients with documented disease progression or ref…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Hackensack Meridian Health

   See if you can join NCT04661137 on ClinicalTrials.gov

10. ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

    The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT06997081 on ClinicalTrials.gov

11. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

    This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Winship Cancer Institute of Emory University, Atlanta, Georgia

    Locations

    24 in total

    Run by

    Heidelberg Pharma AG

    See if you can join NCT04879043 on ClinicalTrials.gov

12. Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

    This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a sm…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Robert Flavell, MD, PhD

    See if you can join NCT05892393 on ClinicalTrials.gov

13. Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities

    The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethn…

    Stage

    Not phased

    Ages

    21 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT04314752 on ClinicalTrials.gov

14. A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

    This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    SCRI Development Innovations, LLC

    See if you can join NCT07637578 on ClinicalTrials.gov

15. A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    22 in total

    Run by

    Celgene

    See if you can join NCT06988488 on ClinicalTrials.gov

16. Elranatamab in R/R Multiple Myeloma

    This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06138275 on ClinicalTrials.gov

17. Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

    This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Illinois at Chicago

    See if you can join NCT05344833 on ClinicalTrials.gov

18. A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer med…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    GSK Investigational Site, Los Alamitos, California

    Locations

    59 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT07227311 on ClinicalTrials.gov

19. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

    The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of e…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida

    Locations

    237 in total

    Run by

    Pfizer

    See if you can join NCT05020236 on ClinicalTrials.gov

20. Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

    Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * • To establish the pharmacokinetic (PK) profile of STAR-LLD at a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Gabrail Cancer & Research Center, Canton, Ohio

    Locations

    2 in total

    Run by

    Starton Therapeutics, Inc

    See if you can join NCT06087653 on ClinicalTrials.gov

21. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Infirmary Cancer Care, Mobile, Alabama

    Locations

    270 in total

    Run by

    Pfizer

    See if you can join NCT06152575 on ClinicalTrials.gov

22. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

    Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

    Stage

    Not phased

    Ages

    19 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT04898790 on ClinicalTrials.gov

23. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). *…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    GSK Investigational Site, Bullhead City, Arizona

    Locations

    44 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT05714839 on ClinicalTrials.gov

24. Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

    This phase II trial tests daratumumab given at a reduced frequency with lenalidomide for maintenance therapy for the cost effective treatment of patients with multiple myeloma post stem cell transplant. Darzalex Faspor (also known as Daratumumab-hyaluronidase) is a combination of two drugs used alo…

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Eden Biltibo

    See if you can join NCT07485647 on ClinicalTrials.gov

25. IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

    The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers als…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    Dickran Kazandjian, MD

    See if you can join NCT06376526 on ClinicalTrials.gov